Filing summary
Entity mismatch: The supplied filing is Onconova Therapeutics, Inc.’s Form 10-Q, not a filing by Traws Pharma, Inc. It covers the quarter and six months ended June 30, 2019; financial statements are unaudited.
Business context and reporting period
Onconova was a clinical-stage oncology company focused primarily on rigosertib, including a Phase 3 trial for higher-risk myelodysplastic syndromes (MDS). It also reported other clinical and preclinical programs. Common-share figures reflect a one-for-fifteen reverse split effective September 25, 2018.
Financial results and liquidity
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | $2.022 million | $0.485 million | $2.090 million | $1.049 million |
| Operating expenses | $5.655 million | $6.124 million | $12.963 million | $12.590 million |
| Operating loss | $3.633 million | $5.639 million | $10.873 million | $11.541 million |
| Net loss attributable to Onconova | $3.561 million | $4.484 million | $11.161 million | $9.574 million |
| Basic and diluted loss per share | $0.60 | $1.10 | $1.89 | $3.76 |
- At June 30, cash and cash equivalents were $5.882 million, down from $16.970 million at December 31, 2018. Six-month operating cash use was $11.510 million; financing provided $0.424 million. No investing cash flow was reported.
- Current assets were $8.429 million and current liabilities $8.746 million, a working-capital deficit of approximately $0.317 million. Total liabilities were $13.126 million. The balance sheet reports a $0.571 million warrant liability; it does not present a conventional borrowings balance.
- Stockholders’ equity became a $4.546 million deficit, from $5.387 million of equity at year-end 2018. Accumulated deficit was $393.057 million.
- No gross margin is presented. Revenue was principally license and collaboration revenue; the filing does not provide a clear standalone product gross margin.
Material changes versus comparable periods
- Q2 revenue rose $1.537 million year over year, primarily from recognition of the HanX rigosertib license. Six-month revenue rose 99% to $2.090 million.
- Q2 operating loss narrowed by $2.006 million, while net loss attributable to Onconova improved by $0.923 million versus Q2 2018. The prior-year quarter included a $0.693 million gain on GBO’s dissolution and a larger favorable warrant fair-value change.
- For the first half, operating loss improved by $0.668 million, but net loss attributable to Onconova increased by $1.587 million. The warrant fair-value change swung from a $1.325 million gain in 2018 to a $0.395 million loss in 2019; the 2018 period also included the GBO dissolution gain.
- First-half general and administrative expense increased 27%, principally due to about $1.6 million of severance and accelerated stock-option vesting costs. R&D expense decreased 8%, partly reflecting lower costs for the oral rigosertib/azacitidine study, partly offset by higher INSPIRE trial costs.
- Cash used in operations rose from $10.133 million to $11.510 million; 2018 financing proceeds were substantially higher ($35.657 million versus $0.424 million in 2019).
Outlook, commentary and risks
- Management said June 30 cash was expected to fund operations and ongoing trials into Q4 2019. It stated additional financing was required and that substantial doubt existed about the company’s ability to continue as a going concern within one year after issuance of the statements.
- HanX’s May 2019 agreement licensed rigosertib in Greater China. Consideration included a $2 million license fee, a $2 million equity investment at a premium, and $2 million in local currency to be escrowed for regional clinical development. The company could receive up to $45.5 million in milestones and tiered royalties. The $2 million fee was received August 8, 2019, net of applicable taxes; the remaining equity investment was still subject to Chinese regulatory approval. The agreement also contemplates possible reimbursement of up to $0.5 million of qualifying excess development spending.
- Management targeted completion of INSPIRE Phase 3 enrollment by the end of 2019 and top-line survival data in the first half of 2020, after 288 death events. The company said the trial was more than 75% enrolled in March 2019. The planned Phase 3 oral rigosertib/azacitidine trial was contingent on additional funding.
- In February and March 2019, the company reduced its workforce by six employees, approximately 24%. The severance-related charge was approximately $1.843 million; $0.810 million remained accrued at June 30, with payments scheduled through February 2020.
- Nasdaq notified the company of a minimum stockholders’ equity deficiency. Nasdaq accepted its compliance plan on July 26, 2019, with a stated deadline of November 18, 2019 to regain compliance. Failure could lead to delisting and impair liquidity and access to capital.
- Other material risks include clinical-trial execution and results, regulatory approval, dependence on further financing and collaborations, potential dilution or unfavorable licensing terms, and the possibility of scaling back or stopping programs. The prior Phase 3 ONTIME trial did not meet its primary overall-survival endpoint.
Most important facts for investors to verify
- Confirm the filing issuer: this document identifies Onconova Therapeutics, Inc. (ticker ONTX), not Traws Pharma, Inc.
- Verify the amount and timing of HanX cash and equity proceeds, including the August 2019 license-fee receipt and the still-pending equity investment.
- Assess cash runway against the stated Q4 2019 estimate, ongoing operating cash burn, and the explicit going-concern uncertainty.
- Track INSPIRE enrollment, the 288-death-event analysis and expected first-half 2020 data timing, along with the funding-dependent oral rigosertib trial.
- Check progress toward Nasdaq’s November 18, 2019 equity-compliance deadline and potential listing consequences.